# US 2012/0253219 A1 · Methods for Recommending Neurophysiological Disorder Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253219 A1
- Document ID: US20120253219A1
- Status: Published application
- Kind: A1
- Application number: 12/575,940
- Filed: 2009-10-08
- Published: 2012-10-04
- Earliest claimed: 1997-09-06
- Assignees: CNS Response, Inc.
- Inventors: Stephen C. Suffin; W. Hamlin Emory
- Web page: https://patentgrep.com/patent/US20120253219A1

## CPC

- A61B 5/4833: {Assessment of subject's compliance to treatment}
- A61B 5/0006: {ECG or EEG signals}
- A61B 5/16: Devices for psychotechnics (using teaching or educational appliances G09B1/00 - G09B7/00); Testing reaction times {; Devices for evaluating the psychological state}
- A61B 5/165: {Evaluating the state of mind, e.g. depression, anxiety}
- A61B 5/372: Analysis of electroencephalograms
- A61B 5/374: Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
- A61B 5/7264: {Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/12: for grand-mal
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 15/00: ICT specially adapted for medical reports, e.g. generation or transmission thereof
- G16H 20/70: relating to mental therapies, e.g. psychological therapy or autogenous training
- A61B 5/1104: {induced by stimuli or drugs (A61B5/1102 takes precedence)}
- A61B 5/7257: {using Fourier transforms}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- G16H 30/40: for processing medical images, e.g. editing
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Neurophysiologic information such as quantitative electroencephalography (QEEG) is used in a method for classifying, diagnosing, and treating physiologic brain imbalances. Neurophysiologic information is also used to guide sample selection in clinical tests for psychopharmacologic drug candidates. Finally, neurophysiologic information is used for remotely assessing and treating patients with physiologic brain imbalances.

## Claims

### Claim 1

A method for recommending therapy for a patient having a behaviourally diagnosed psychiatric condition, wherein a plurality of monopolar or bipolar EEG signals are obtained from the patient, and a plurality of patient univariate measures are extracted from the patient EEG signals, each univariate measure representing a quantitated deviation from a plurality of monopolar or bipolar EEG signals from an asymptomatic normal population, wherein the method comprises:
a) using an outcomes database that includes symptomatic profiles for symptomatic individuals who exhibit clinical manifestations of psychiatric imbalances with known therapy outcomes, the symptomatic profiles being derived from selected combinations of two or more univariate EEG signals, the outcomes database including symptomatic profiles comprising pre-therapy profiles and post-therapy profiles for the symptomatic individuals;
b) deriving one or more patient multivariate EEG descriptors from selected combinations of two or more patient univariate measures to form a patient profile;
c) comparing the patient profile to the symptomatic pre-therapy profiles in the outcomes database to identify one or more individuals who have a symptomatic profile similar to the patient profile, and
d) recommending at least one therapy for the patient from among those therapies with known outcomes for the individuals of the symptomatic population who have a symptomatic profile similar to the patient profile, wherein the recommended therapies are selected from the symptomatic post-therapy profiles that deviate less from the asymptomatic normal population than the pre-therapy profiles corresponding to the symptomatic post-therapy profiles.

### Claim 2 (depends on 1)

The method of claim 1, wherein the asymptomatic normal population EEG signals comprise one or more of the absolute power, relative power, coherence, asymmetry, or ratios thereof, of EEG signals from selected anatomic brain regions.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient or the symptomatic univariate measures are selected so that the patient or the symptomatic multivariate descriptors comprise representations of the absolute power, relative power, coherence, asymmetry, or ratios thereof, of EEG signals from selected anatomic brain regions.

### Claim 4 (depends on 3)

The method of claim 3, wherein the multivariate descriptors further comprise representations of the EEG information in one or more selected frequency bands.

### Claim 5 (depends on 4)

The method of claim 4, wherein the frequency bands comprise one or more of the delta, theta, alpha, or beta bands.

### Claim 6 (depends on 3)

The method of claim 3, wherein the selected anatomic regions comprise one or more of the anterior, posterior, left side, right side, or the entire brain.

### Claim 7 (depends on 1)

The method of claim 1, wherein the patient profile and symptomatic profile are similar if the association of their values is statistically robust.

### Claim 8 (depends on 1)

The method of claim 1, wherein the recommended therapy comprises one or more of electroconvulsive therapy, electromagnetic therapy, pharmacologic therapy, neuromodulation therapy, or verbal therapy.

### Claim 9 (depends on 1)

The method of claim 1, wherein the known outcome comprises normalizing the EEG signals or of normalizing the behaviorally-diagnosed psychiatric condition in one or more individuals in the symptomatic population.

### Claim 10 (depends on 1)

The method of claim 1, wherein a plurality of asymptomatic multivariate descriptors are derived from the asymptomatic normal population EEG signals.

### Claim 11 (depends on 1)

The method of claim 1, wherein the patient multivariate descriptors comprise patient quantified functional information, wherein the quantified functional information reflects physiologic brain functioning in a plurality of anatomic regions of the brain.

### Claim 12 (depends on 11)

The method of claim 11, wherein the patient quantified functional information is compared with quantified functional information from at least one reference population comprising individuals exhibiting similar symptomatic responsivity profiles thereby identifying quantitated deviations of the patient quantified functional information from the at least one reference population.

### Claim 13 (depends on 11)

The method of claim 11, wherein a plurality of patient multivariate descriptors are derived from the quantitated deviations, wherein each multivariate descriptor is responsive to a plurality of the quantitative deviations, and wherein multivariate descriptors together form a profile for the patient representing the patient's physiologic brain functioning.

### Claim 14 (depends on 11)

The method of claim 11, wherein the quantified functional information reflects an eyes-closed, background state.

### Claim 15 (depends on 1)

The method of claim 1, wherein the profiles are compared by performing rule-based classification of profile similarity.

### Claim 16 (depends on 1)

The method of claim 1, wherein the profiles are compared by performing a statistical assessment of the robustness of profile similarity.

### Claim 17 (depends on 1)

The method of claim 1, wherein the therapies are recommended for the patient profile that is similar to the pretherapy profile of the symptomatic individual, wherein the symptomatic individual's post-therapy profile deviates less from normal than their corresponding pre-therapy profile.

### Claim 18 (depends on 1)

The method of claim 1, wherein the univariate measures are generated using a Fast Fourier Transformation of the EEG information.

### Claim 19 (depends on 1)

The method of claim 1, wherein the quantified deviations responsive to only a single univariate measure are expressed as a Z score.

### Claim 20 (depends on 12)

A method according to claim 12, wherein the reference population is the asymptomatic normal reference population comprising individuals who are asymptomatic for behaviorally-diagnosed psychiatric conditions.

### Claim 21 (depends on 12)

The method of claim 12, wherein the reference population is the symptomatic population and the patient quantified functional information is compared with quantified functional information from the symptomatic population to produce a group of similarities for the patient.

### Claim 22 (depends on 21)

The method of claim 21, wherein the group of similarities are organized by multivariate descriptors to provide a similarities profile.

### Claim 23 (depends on 1)

The method of claim 1, wherein the symptomatic individuals in the symptomatic population exhibit behavioral indicia of physiologic brain imbalances.

### Claim 24 (depends on 1)

The method of claim 1, wherein the behaviorally-diagnosed psychiatric condition comprises a brain pathology.

### Claim 25 (depends on 1)

The method of claim 1, wherein the therapy is selected from the group consisting of drug therapy, electroconvulsive therapy, electromagnetic therapy, neuro-modulation therapy, verbal therapy, and combinations thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the therapy is drug therapy and the drug is selected from the group consisting of a psychotropic agent, a neurotropic agent, multiple of psychotropic agents or neurotropic agents, and any combination thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the drug has a direct or indirect effect on the CNS system of the patient.

### Claim 28 (depends on 27)

The method of claim 27, wherein the behaviorally-diagnosed psychiatric condition comprises a panic disorder, and the drug therapy comprises a drug selected from the group consisting of valproic acid, clonazepam, carbamazepine, methylphenidate and dextroamphetamine.

### Claim 29 (depends on 27)

The method of claim 27, wherein the behaviorally-diagnosed psychiatric condition comprises an eating disorder, and the drug therapy comprises a drug selected from the group consisting of methylphenidate and dextroamphetamine.

### Claim 30 (depends on 27)

The method of claim 27, wherein the behaviorally-diagnosed psychiatric condition comprises a learning disorder, and the drug therapy comprises a drug selected from the group consisting of amantadine, valproic acid, clonazepam and carbamazepine.

### Claim 31 (depends on 1)

The method of claim 1, wherein after one or more of the recommended therapies are administered to the patient a plurality of follow-up multivariate descriptors are derived from quantified deviations from the reference population of follow-up quantified functional information and a plurality of follow-up multivariate descriptors are derived from the patient when in the selected physiologic brain state.

### Claim 32 (depends on 31)

The method of claim 31, wherein the recommended therapy is changed depending on the patient's follow-up multivariate descriptors.
